NRAS has been informed about a study which is inviting people living with RA to take part in and we are making you aware of this in case you should wish to take part in the study.
GlaxoSmithKline Research & Development Limited is developing a new medicine which is a potential new treatment for RA. The study is to test the safety and efficacy of GSK2982772, an investigational drug (‘investigational’ means that the drug has not yet been approved for general use).
You may be able to take part in the 203168 Study if you:
Are between 18 and 75 years.
Have been diagnosed with RA and are currently experiencing symptoms.
Are being treated with at least one conventional Disease Modifying Anti-Rheumatic drug (e.g. methotrexate, sulfasalazine, hydroxychloroquine and /or leflunomide).
You would need to be able to travel to London, Southampton, Oxford or Cardiff, taking part about 10 times over about 20 weeks. Please visit nras.org.uk/clinical-trials for further information.
There is no obligation to take part in this study and once you have read more information on the website you can then decide if you would like to take part.